Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Alexander Scheer has been named chief scientific officer of Aelin Therapeutics. Prior, Scheer was chief scientific officer of Erytech Pharma.
Pini Ben-Or has joined Aktana as the company’s chief science officer. Prior to this role, Ben-Or was global head of analytics of NICE Actimize. Colm Callan, previously chief financial officer at WageWorks, has also joined Aktana as its chief financial officer. Aktana has also hired Kate Terrell to the role of chief people officer. Previously, Terrell was chief human resources officer for Driscoll’s berry company. Mike Weber has taken the role of vice president of product at Aktana, departing his most recent role of senior director of product management at Salesforce.
AMAG Pharmaceuticals appointed Scott Myers to the role of president and CEO. Myers was previously chairman and CEO of Rainier Therapeutics.
Cheryl Blanchard has assumed the roles of president and CEO of Anika, a joint preservation and regenerative therapies company. Before joining Anika, Blanchard was president and CEO of Microchips Biotech.
Serena Hung has been named head of clinical development of Arkuda Therapeutics. Hung was most recently a clinical development lead at WAVE Life Sciences. Arkuda Therapeutics has also appointed Raymond Hurst to the role of vice president of pharmacology. Hurst was director of biology and pharmacology at Concert Pharmaceuticals before joining Arkuda.
Richard Gregory has been appointed acting chief scientific officer of CANbridge Pharmaceuticals. Most recently, Gregory was executive vice president and chief scientific officer at ImmunoGen.
Anand Varadan has been named executive vice president and chief commercial officer of Chiasma. Prior to this appointment, Varadan served as chief commercial officer of Karyopharm Therapeutics.
Laura Jones has been named president of CrO Biosciences.
Brett Kleger has been named CEO of Datacubed Health. Kleger was tapped from IQVIA Technologies, where he served as chief commercial officer of DrugDev.
David Cook has been named chief scientific officer of Forma Therapeutics. Previously, Cook was executive vice president of R&D and chief scientific officer of Seres Therapeutics.
David Leppert has been named chief medical officer of GeNeuro. Leppert will retain his academic appointment at the University of Basel, where he serves as associate professor in neurology.
Sue Desmond-Hellmann has joined Google Ventures as a drug expert and adviser. Most recently, Desmond-Hellmann was the CEO of the Bill & Melinda Gates Foundation.
The Institute for Clinical and Economic Review (ICER) has named Jon Campbell senior vice president for health economics. Campbell will transition out of his position of associate professor at the University of Colorado’s Anschutz Medical Campus.
Mark Exley has been appointed chief scientific officer of Philadelphia-based biotech Imvax. Exley was most recently vice president of cellular immunology at AgenTus.
Incyte appointed Christine Lennon to general manager of Incyte Biosciences Canada. Lennon was president and CEO of Epigene Therapeutics before joining Incyte.
MorphoSys appointed Roland Wandeler to the role of chief commercial officer. Most recently, Wandeler was corporate vice president and general manager of Amgen’s U.S. bone health and cardiology business unit.
Susan McGaurn has been named senior director of medical affairs at Mycovia. Previously, McGaurn was director of medical information and call centers at Endo Pharmaceuticals.
Frédéric Pilotaz has been appointed to the role of vice president of technology and pharmaceutical sciences at Oculis. Before joining Oculis, Pilotaz was senior director and head of chemistry manufacturing and controls and pharmaceutical operations at Nicox.
Personal Genome Diagnostics
Megan Bailey has been promoted from her role of chief operating officer to CEO of Baltimore-based Personal Genome Diagnostics.
Lutz Hilbrich will now serve as ProBioGen’s CEO. Prior to this role, Hilbrich was vice president and head of biosimilars platform of Sanofi China.
Kelly Martin, prior CEO of Elan Pharmaceuticals, will now lead Radius Health as the company’s CEO.
David Michelson has been named chief medical officer of Regenacy Pharmaceuticals. Previously, Michelson was chief medical officer of Proclara Biosciences.
Relmada Therapeutics appointed Brian Walter to the role of vice president of regulatory affairs. Walter most recently served as vice president of regulatory affairs at REGENXBIO.
Repertoire Immune Medicines
Repertoire Immune Medicines has named Andrea DiFabio executive vice present and chief legal and corporate administration officer. DiFabio was tapped from Codiak BioSciences, where she served as chief legal officer and secretary. Tim Harris has been appointed executive vice president of corporate development of Repertoire. Most recently, Harris was the executive vice president of research and development at Bioverativ. Repertoire has also named Lucia Celona executive vice president and chief human resources officer. Previously, Celona was chief people officer at Apellis Pharmaceuticals.
Rudolf Baumgartner has been hired to the role of chief medical officer and head of clinical development at Saniona. Baumgartner was previously chief medical officer for the Flatley Discovery Lab.
Gilad Bar-Lev has been named CEO of Therapix Biosciences. Bar-Lev joins the company after serving as CEO of Carnie Capital.
Xilio Therapeutics has found its newest chief medical officer in Martin Huber. Prior to this role, Huber was senior vice president and chief medical officer at Tesaro.